n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide has been researched along with Cancer of Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Q; Luo, J; Ou, S; Peng, R; Qin, X; Wang, S; Wei, H | 1 |
2 other study(ies) available for n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide and Cancer of Lung
| Article | Year |
|---|---|
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Medical Oncology | 2023 |
[China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)].
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |